N/A N=47 Antecedents of Obesity: Fetal Measures of Adiposity
Obesity
Primary: Infant Adiposity at 24-72 Hours Following Birth — 11 Percentage of total body weight
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 Activity, Adiposity, and Appetite in Adolescents 2
Obesity · Metabolic Disease · Insulin Sensitivity
Primary: Appetite- Subjective — 9239.4; 7879.6; 6130.5; 8970.0 score on a scale*min
N/A N=10 Measurement of Body Fat in Infants
Brown Adipose Tissue · Body Composition
Primary: Whole Body Fat Mass — 20.8 percentage of fat mass
N/A N=254 Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
Pregnancy; Nutritional Diseases
Primary: Infant Fat Mass (FM) — 3050.7; 3673.6 g
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
N/A N=12 The Effects of Alcohol Consumption on Central Adiposity
Alcohol Drinking · Weight Loss · Adiposity
Primary: Change in Central (Abdominal) Adiposity — -0.250; -0.071 kg — p=<0.231
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=31 Activity, Adiposity, and Appetite in Adolescents 2 Intervention
Obesity · Energy Balance · Appetite
Primary: Appetite- Subjective — 6282; 8738 score*minute
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 4 N=51 Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
Schizophrenia · Type 2 Diabetes Mellitus
Primary: Change in Total Body Fat (kg). — 0.15; -1.77; -1.27 change in kilograms — p=0.03
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
N/A N=93 Exercise Regulation of Human Adipose Tissue
Healthy · Obese · Diabetes Mellitus, Type 2
Primary: Changes in Human Adipose Tissue Characteristics Following Exercise Training — 25.45; 34.12; 38.06; 27.05 body fat %
Phase 4 N=40 Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Obesity, Visceral
Primary: Change in Glycerol Enrichment — 6.5; 1.4 Percentage change — p=0.0053
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
N/A N=137 Beige Fat, Energy, and the Natriuretic Peptide System
Obesity
Primary: Adipose Tissue Gene Expression of UCP1 (Uncoupling Protein 1)- Differences by Obesity Status — 7.79; 24.33 fold change — p=<0.01
N/A N=18 The Effects of Chiropractic in a Population With High Central Adiposity
Abdominal Obesity
Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion
N/A N=67 Obesity Risk in African American Women is Determined by a Diet-by-phenotype Interaction
Diet Modification
Primary: Total Energy Expenditure — 2411; 2316; 2318; 2179 kcal/day
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
N/A N=95 Adapting Diet and Action for Everyone (ADAPT+)
Pediatric Obesity
Primary: Acceptability — 3.91; 3.85 score on a scale
N/A N=40 Fat Perception in Humans (09-0873)
Obesity
Primary: Oleic Acid Detection Level — -0.3; -1.2; -1.0 log10 (%W/V OLEIC ACID) — p=0.05
Phase 2 N=80 Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.
Obesity
Primary: Changes in Body Fat Mass. — 22.65; 23.04; 22.28; 23.17 kg — p=<0.05
N/A N=26 Effect of Increased Free Fatty Acids on Leptin Function
Obesity · Leptin Resistance
Primary: Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels — 7147; 11725; 11898; 28060 pM*min
Phase 2 N=20 Study to Evaluate ARD-101 in Adults With Obesity
Obesity
Primary: Relative Change in Body Weight (%) — -0.33; 0.38 Percentage of body weight change
N/A N=65 Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
Weight Gain · Healthy Subjects · Obesity
Primary: Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA) — 80.0; 81.3; 80.5 Percentage of total HUFA